🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are increasing around the world, with data suggesting in excess of 82 million new cases annually. Particularly high rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the context of rising global incidence, the spread of superbugs and the highly restricted available drugs at this time.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Receive Approval

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists hope that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in the same week. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This approval signifies a major breakthrough in the treatment of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Results and Global Access

As per results detailed in a major medical journal, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which involves a dual-drug approach. The research involved hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have shared optimism. Access to a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is viewed as essential to reduce the burden of the infection for individuals and to halt the transmission of untreatable gonorrhoea globally.